Biegel & Waller’s AbbVie ABBV Stock Holding History

Biegel & Waller’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,178	Closed	-$201K	–	78
2018 Q4	$201K	Buy	2,178 +1	+0%	+$88	0.12%	68
2018 Q3	$206K	Buy	+2,177	New	+$206K	0.12%	70
2018 Q1	–	Sell	-2,433	Closed	-$235K	–	58
2017 Q4	$235K	Hold	2,433	–	–	0.14%	49
2017 Q3	$216K	Buy	+2,433	New	+$185K	0.14%	46
2017 Q1	–	Sell	-4,230	Closed	-$259K	–	51
2016 Q4	$259K	Buy	+4,230	New	+$258K	0.18%	36

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Biegel & Waller's ABBV Position: Q1 2019 in Review

Biegel & Waller sold out of AbbVie (ABBV) in Q1 2019, closing a stake of 2,178 shares — an estimated $201K sold.

Biegel & Waller first reported a position in ABBV in Q4 2016 and held it in 5 quarters. The position peaked at $259K in Q4 2016. 2,034 funds tracked by Wall St. Rank hold ABBV as of Q1 2019.

Biegel & Waller reported no remaining AbbVie position as of Q1 2019 after selling out during the quarter.
Biegel & Waller sold 2,178 AbbVie shares in Q1 2019, an estimated $201K.
Biegel & Waller first reported a position in AbbVie in Q4 2016 and held it in 5 quarters.
Biegel & Waller's AbbVie position peaked at $259K in Q4 2016.
2,034 funds tracked by Wall St. Rank held AbbVie as of Q1 2019.

Based on Biegel & Waller's 13F filing for Q1 2019, filed 1 May 2019.